

Vitalgen to Present Advanced Gene Therapy Pipeline and Parkinson's Disease Progress at BIO International Convention 2025

Vitalgen, a pioneer in transformative gene therapies with vertically integrated proprietary platforms, will participate in the upcoming BIO 2025 Convention

BOSTON, MA, UNITED STATES, April 15, 2025 /EINPresswire.com/ -- Shanghai [Vitalgen](#) BioPharma

“

We're excited to present Vitalgen's latest breakthroughs in gene therapy at BIO 2025”

Dr. David Wu, Ph.D., Director of Business Development and Partnerships

Co., Ltd. ("Vitalgen"), a pioneer in transformative gene therapies with vertically integrated proprietary platforms, announced it will participate in the upcoming BIO 2025 Convention, where it will showcase its innovative gene therapy pipeline and present significant progress in its Parkinson's disease program.

The Vitalgen team, led by Dr. Hua Lv, Ph.D., Head of Clinical Development and Dr. David Wu, Ph.D., Director of Business Development and Partnerships, will share updates on the

company's cutting-edge gene therapy platforms and clinical advancements, with special focus on its promising neurodegenerative disease treatments.

"We're excited to present Vitalgen's latest breakthroughs in gene therapy at BIO 2025," said Dr. Wu. "Our progress, particularly in the Parkinson's disease program, demonstrates the potential of our proprietary technology platforms to address significant unmet medical needs."

Vitalgen's presentation will highlight its VGN-R09b program for AADC/Parkinson's disease, which has received IND approval from both the FDA (PD) and NMPA. The program has shown positive results in investigator-initiated trials (IIT), with Phase III trials currently ongoing for AADC and Phase I/II trials for Parkinson's disease.

Founded in March 2020 in Shanghai, Vitalgen has rapidly established itself as a leader in gene therapy development, having raised \$160 million through Series B+ funding. The company focuses on ophthalmology and neurodegenerative diseases, with two programs in Phase III, two in Phase I/II, and two in IIT studies.

Vitalgen's comprehensive approach to gene therapy is powered by three key proprietary

technology platforms:

1. The ViVec® AAV Capsid Screening Platform, which has developed proprietary AAV serotypes with CNS and liver tropism
2. The ViCas® CRISPR DNA Editing Platform, featuring the advanced AaCas12bMax system
3. Proprietary Lipid Nanoparticle Platforms, including the ViLNP® family of delivery systems

The company's state-of-the-art facilities include 2,500 m² of R&D sites and 8,500 m² of manufacturing plants located in Shanghai's Waigaoqiao free trade zone. The AAV commercial manufacturing facility features two production lines with 50/200L and 500L bioreactors that comply with both China GMP and US cGMP standards.

Visitors to BIO 2025 are invited to connect with Dr. Wu and the Vitalgen team to explore potential partnerships and collaboration opportunities in gene therapy development and commercialization.

About Vitalgen

Vitalgen BioPharma Co., Ltd. is a patient-focused, innovation-driven biotechnology company developing transformative gene therapies. With a team of over 140 R&D professionals and 10+ pipeline candidates, Vitalgen is committed to delivering breakthrough treatments for patients with rare and common diseases. For more information, visit <http://www.vitalgen.com/en/>.

Contact Information

Dr. David Wu, Ph.D.
Director of Business Development and Partnerships
cg.wu@vitalgen.com
+86 19512392817

David Wu
Vitalgen BioPharma
[email us here](#)

This press release can be viewed online at: <https://www.einpresswire.com/article/803326041>

EIN Presswire's priority is source transparency. We do not allow opaque clients, and our editors try to be careful about weeding out false and misleading content. As a user, if you see something we have missed, please do bring it to our attention. Your help is welcome. EIN Presswire, Everyone's Internet News Presswire™, tries to define some of the boundaries that are reasonable in today's world. Please see our Editorial Guidelines for more information.

© 1995-2025 Newsmatics Inc. All Right Reserved.